Ratings for Alpine Immune Sciences ALPN were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 4 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.5, a high estimate of $35.00, and a low estimate of $22.00. This current average reflects an increase of 45.41% from the previous average price target of $19.60.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alpine Immune Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Driscoll | Wedbush | Raises | Outperform | $35.00 | $26.00 |
| Joseph Pantginis | HC Wainwright & Co. | Raises | Buy | $32.00 | $17.00 |
| Robert Driscoll | Wedbush | Maintains | Outperform | $26.00 | - |
| Gregory Renza | RBC Capital | Raises | Outperform | $22.00 | $19.00 |
| Robert Driscoll | Wedbush | Raises | Outperform | $26.00 | $19.00 |
| Michael Ulz | Morgan Stanley | Raises | Overweight | $30.00 | $17.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alpine Immune Sciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Alpine Immune Sciences compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Alpine Immune Sciences's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alpine Immune Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Alpine Immune Sciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Alpine Immune Sciences
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Key Indicators: Alpine Immune Sciences's Financial Health
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Alpine Immune Sciences displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 20.03%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Alpine Immune Sciences's net margin excels beyond industry benchmarks, reaching -116.72%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Alpine Immune Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of -7.08%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Alpine Immune Sciences's ROA excels beyond industry benchmarks, reaching -4.75%. This signifies efficient management of assets and strong financial health.
Debt Management: Alpine Immune Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
What Are Analyst Ratings?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
